Liothyronine for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Liothyronine for Health & Longevity

Created on 08/09/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Liothyronine is prescription active thyroid hormone. It replaces deficiency, may help selected residual symptoms on standard replacement, and can add on for depression that has not fully responded. Trials do not reliably show combination outperforming optimized standard replacement alone. Safety evidence for regulated, monitored use is more reassuring than early fears; not for weight loss with normal thyroid function. (Full Review)

Protocol

Combination LT4/LT3 (integrative and some academic clinics)
~5–12.5 mcg T3 1–2×/day
Reduce T4 ~25–50 mcg; trials often 5–15 mcg/day total T3 with T4
Half-life and split dosing
Split immediate-release doses
When total T3 exceeds low single-digit mcg or post-dose jitter; split morning/midday if insomnia or afternoon crash; avoid late-evening peaks
Depression augmentation
25–50 mcg/day
Specialty off-label; continue antidepressant; weeks to months
Time to effect
Hypothyroid / residual symptoms
1–3 weeks per dose step
Full assessment after several weeks on a stable regimen
Mood (depression add-on)
1–3 weeks per dose step
Antidepressant continued; full assessment after several weeks on a stable regimen
Heart rate / temperature
Within hours of a dose
Peak serum level roughly 2–4 hours (immediate-release)

Benefits

Contraindications
  • Uncorrected adrenal insufficiency
  • Untreated thyrotoxicosis
  • Weight-loss use in euthyroid individuals
    •
Key Interactions
  • Acute myocardial infarction (often avoid initially)
  • Anticoagulants – warfarin and similar
  • Antidiabetic agents including insulin and sulfonylureas
  • Sympathomimetics and stimulants (e.g., pseudoephedrine, amphetamines, high-dose caffeine)
  • Ketamine, tricyclic antidepressants, and some SSRIs
  • Bile acid sequestrants (cholestyramine, colesevelam), sucralfate, cation-containing antacids, iron, calcium, some phosphate binders (separate dosing, commonly ≥4 hours)
  • Enzyme inducers and modulators of binding proteins (e.g., certain anticonvulsants, estrogen therapy)
  • Supplements with additive thyroid or adrenergic effects (iodine megadoses, high-dose kelp, undeclared T3/T4 in "thyroid support" or "adrenal" products, yohimbine-like stimulants)
  • Pregnancy (prefer T4; avoid routine T3 combination); breastfeeding under specialty input
  • Adults ≥60–65 with cardiac disease, recent MI (<90 days), uncontrolled hypertension, active atrial fibrillation with rapid ventricular response
    •

Risk & Side Effects

  • High: Symptoms and signs of iatrogenic thyrotoxicosis; cardiac arrhythmia and ischemia risk with excess exposure
    •
  • Medium: Reduced bone mineral density with chronic excess; observational cardiovascular signals
    •
  • Low: Adrenal crisis unmasking in unrecognized adrenal insufficiency; hypersensitivity and formulation excipient reactions
    •
  • Speculative: Long-term subclinical cardiac remodeling at high-normal free T3
    •

Monitoring

Marker Target Why
TSH ~0.5–2.5 mIU/L (context-dependent) Pituitary sense of thyroid tone
Free T4 Mid-normal on T4-only; may run lower on T4/T3 Prohormone reservoir
Free T3 Mid-normal without peak toxicity Active hormone exposure (draw timing matters)
Resting heart rate Individually stable; investigate sustained rise Early thyrotoxic signal
Blood pressure Age-appropriate normal Adrenergic load
ECG No new ischemia/arrhythmia Cardiac safety
DXA (bone density) T-score context by age/sex Long-term excess risk
Fasting lipid panel Individual cardiometabolic targets Metabolic context

Cadence: About 4–6 weeks after each dose change (sooner if excess symptoms), then every 3–6 months once stable; bone density on a multi-year cadence when risk warrants

Qualitative Assessment

  • Energy stability across the day (not only a 2-hour post-dose lift)
  • Sleep onset and maintenance
  • Resting heart-rate trend and exercise tolerance
  • Mood and cognitive clarity (especially if treating residual hypo symptoms or depression)
  • Heat/cold tolerance, tremor, bowel pattern
  • Absence of chest pain, unaccustomed dyspnea, or irregular heartbeat
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.